 |
|
| |
Stephen Saad (55) |
|
|
Group Chief Executive |
| |
Appointed: January 1999 |
|
|
Qualifications: CA(SA), PhD (Commerce) Honoris Causa |
| |
Responsibilities: Stephen is a founding shareholder of Aspen and his responsibilities extend to include strategic positioning of
Aspen as a leading multinational pharmaceutical company, global transactions, geographic expansion and product diversification
of Aspen in developed and emerging markets. |
|
| |
|
|
 |
|
| |
Gus Attridge (58) |
|
|
Deputy Group Chief Executive (Finance Director) |
| |
Appointed: January 1999 |
|
|
Qualifications: CA(SA) |
| |
Responsibilities: Gus is a founding shareholder of Aspen and is responsible for the strategic and financial wellbeing of the Group
while also identifying and pursuing appropriate corporate opportunities and global transactions that will further benefit Aspen and
its stakeholders.
|
|
| |
|
|
 |
|
| |
Sean Capazorio (54) |
|
|
Group Finance Officer |
| |
Appointed: January 1999 |
|
|
Qualifications: CA(SA) |
| |
Responsibilities: Sean is responsible for all of the Group’s finance functions across Aspen’s 55 businesses and also assesses
business performance and identifies business improvement opportunities. |
|
| |
|
|
 |
|
| |
Lorraine Hill (56) |
|
|
Group Operating Officer and Responsible Pharmacist |
| |
Appointed: January 1999 |
|
|
Qualifications: BPharm |
| |
Responsibilities: Lorraine is responsible for multiple operational areas of the business including strategic manufacturing,
pharmaceutical affairs, new product development, strategic procurement and IT. In addition, she plays an integral role in
negotiation and implementation of new business initiatives including global transactions. |
|
| |
|
|
 |
|
| |
Samer Kassem (45) |
|
|
Chief Executive Officer, Aspen Global Incorporated CEO |
| |
Appointed: May 2008 |
|
|
Qualifications: CMA, CFM, CBM, MBA |
| |
Responsibilities: Samer joined the Group with the responsibility of establishing the company to direct its global operations. He
has been integrally involved in the negotiation, completion and integration of strategic acquisitions, the setting up of the Group’s
global businesses as well as the trading and supply structures to support these. |
|
| |
|
|
 |
|
| |
Stavros Nicolaou (54) |
|
|
Group Senior Executive Strategic Trade |
| |
Appointed: January 1999 |
|
|
Qualifications: B.Pharm, FPS (SA), PhD (Medicine)
Honoris Causa |
| |
Responsibilities: Stavros plays a pivotal role in the initiation of business development opportunities and is also key to the
building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders. |
|
| |
|
|
 |
|
| |
Carnie van der Linde (50) |
|
|
Group Commercial Head |
| |
Appointed: May 2016 |
|
|
Qualifications: BTech: Dental Technology |
| |
Responsibilities: Carnie is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial
Pharmaceutical businesses in Europe CIS, Canada, Spanish Latin America, Brazil, Middle East North Africa and Sub-Saharan Africa. |
|
| |
|
|
 |
|
| |
Trevor Ziman (48) |
|
|
Asia Pacific CEO |
| |
Appointed: May 2001 |
|
|
Qualifications: CA(SA) |
| |
Responsibilities: Trevor is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial
Pharmaceutical businesses in Australasia, China, Japan, the Philippines, Taiwan, Malaysia and Hong Kong as well as trade into the
rest of the Asia Pacific region. He plays a leading role in all transactional activity in the region. |
|
